8DY2

Crystal Structure of spFv GLK1

Summary for 8DY2

• Entry DOI: 10.2210/pdb8dy2/pdb
• Descriptor: spFv GLK1 LH, SULFATE ION (3 entities in total)
• Functional Keywords: scfv, stapled scfv, spfv, germline scfv, single chain fv, scfv stabilizations, antibody, immune system
• Biological source: Homo sapiens
• Total number of polymer chains: 4
• Total formula weight: 106341.48

Authors

Luo, J.,Boucher, L.E. (deposition date: 2022-08-03, release date: 2023-05-03, Last modification date: 2024-10-16)

Primary citation

Boucher, L.E.,Prinslow, E.G.,Feldkamp, M.,Yi, F.,Nanjunda, R.,Wu, S.J.,Liu, T.,Lacy, E.R.,Jacobs, S.,Kozlyuk, N.,Del Rosario, B.,Wu, B.,Aquino, P.,Davidson, R.C.,Heyne, S.,Mazzanti, N.,Testa, J.,Diem, M.D.,Gorre, E.,Mahan, A.,Nanda, H.,Gunawardena, H.P.,Gervais, A.,Armstrong, A.A.,Teplyakov, A.,Huang, C.,Zwolak, A.,Chowdhury, P.,Cheung, W.C.,Luo, J.
"Stapling" scFv for multispecific biotherapeutics of superior properties.
Mabs, 15:2195517-2195517, 2023

PubMed Abstract: Single-chain fragment variable (scFv) domains play an important role in antibody-based therapeutic modalities, such as bispecifics, multispecifics and chimeric antigen receptor T cells or natural killer cells. However, scFv domains exhibit lower stability and increased risk of aggregation due to transient dissociation ("breathing") and inter-molecular reassociation of the two domains (VL and VH). We designed a novel strategy, referred to as stapling, that introduces two disulfide bonds between the scFv linker and the two variable domains to minimize scFv breathing. We named the resulting molecules stapled scFv (spFv). Stapling increased thermal stability (Tm) by an average of 10°C. In multiple scFv/spFv multispecifics, the spFv molecules display significantly improved stability, minimal aggregation and superior product quality. These spFv multispecifics retain binding affinity and functionality. Our stapling design was compatible with all antibody variable regions we evaluated and may be widely applicable to stabilize scFv molecules for designing biotherapeutics with superior biophysical properties.

PubMed: 37074212
DOI: 10.1080/19420862.2023.2195517

Experimental method

X-RAY DIFFRACTION (1.65 Å)